Pacific Bio (PACB) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Rivian shares slip ahead of Thursday earnings release
- Six killed in cyclone off India's eastern coast
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results
August 3, 2021 4:06 PM EDTMENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021.
Record second quarter revenue reflects continued quarter-over-quarter growth
Revenue for the second quarter of 2021 was $30.6 million, representing an 79% increase compared with $17.1 million for the second quarter of 2020. The Company placed 38 Sequel II/IIe systems during the second quarter of 2021 compared to 23 Sequel II systems placed in the second quarter of 2020 and 41 Sequel II/IIe systems placed during the first quarter of 2021, bringing the... More



